Approval · Notice of Compliance 29368 · 2022
SUNLENCA: Notice of Compliance 29368
Issued November 2, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 29368
- Date
- November 2, 2022
- Company
- Gilead Sciences Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Priority-NAS
Products in this notice
Medicinal ingredients
- LENACAPAVIR SODIUM 309 MG per ML
- LENACAPAVIR SODIUM 300 MG per TAB